12:10 PM EST - MDS Inc. : said it has signed agreements to divest its remaining MDS Pharma Services Early Stage business, which provides Discovery through Phase IIa clinical trial services to biotechnology and pharmaceutical companies, for $45 million and certain minority equity interests. The $45 million purchase price includes a five-year, $25-million note and $20 million in cash that will be adjusted for working capital and other items; after currently projected adjustments, the $20-million cash payment is estimated to result in net cash proceeds of approximately $7 million. MDS Inc.
shares T.MDS are trading down $0.08 at $8.36.
